Last reviewed · How we verify
NCT02982798
The PK Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 in Healthy Male Volunteers
Phase 1 trial testing Metformin + Rosuvastatin in Diabetes in 40 participants. Completed in 31 January 2018.
30 August 2017
Quick facts
| Lead sponsor | Jeil Pharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 6 July 2017 |
| Primary completion | 30 August 2017 |
| Estimated completion | 31 January 2018 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Metformin + Rosuvastatin — full drug profile →
- JLP-1310 — full drug profile →
Conditions studied
- Diabetes — all drugs for Diabetes →
- Hyperlipidemia — all drugs for Hyperlipidemia →
Sponsor
Jeil Pharmaceutical Co., Ltd. — full company profile →
Who can join
19 and older, male only, with Diabetes or Hyperlipidemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A randomized, open-label, single dose, crossover study to compare the pharmacokinetic characteristics of the co-administration of metformin SR and rosuvastatin and JLP-1310 in healthy male volunteers
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02982798
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Metformin + Rosuvastatin
Trials testing the same drug.
- NCT02827903 — Metformin/Rosuvastatin Combination Therapy With in Patients With Type 2 Diabetes and Dyslipidemia · Phase 3 · completed
Other recruiting trials for Diabetes
Currently open trials in the same condition.
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
- NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
- NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
- NCT07417865 — ECHO Diabetes FQHC · recruiting
Other Jeil Pharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT07115706 — JAQBO® Tab. 20 mg(Zastaprazan Citrate) in Erosive GERD · not yet recruiting
- NCT06952855 — Observationa Study is a Prospective and Multi-institutional Observational Study. · completed
- NCT06431399 — To Evaluate the Safety, Pharmacokinetic Characteristics and the Effect of Food After Administration of JLP-2004 · Phase 1 · recruiting
- NCT06169059 — To Evaluate the Safety and Pharmacokinetic Characteristics After Multiple Administration of JC-013 and JLP-2004 · Phase 1 · completed
- NCT06165965 — To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008 · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02982798 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jeil Pharmaceutical Co., Ltd.
- Last refreshed: 29 March 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02982798.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing